Distribution of ABO blood groups and Rh factor in benign and malign thyroid nodules

Year 2023, Volume: 6 Issue: 2, 462 - 466, 27.03.2023

Muzaffer Serdar Deniz

https://doi.org/10.32322/jhsm.1243805

Abstract

Aim: Many factors affect the diagnostic value of the fine-needle aspiration biopsy applied for these thyroid nodules. I aimed to investigate whether one of these factors would be ABO blood groups and Rh factor and examine the relationship of these factors with the Bethesda categorization. Additionally, I aimed to evaluate ABO blood groups and Rh factors in patients with thyroid cancer.
Material and Method: This study was planned in a cross-sectional retrospective design. The data of the patients were obtained from the hospital data bank. In the analysis of 801 patients following the acceptance criteria, 412 patient data were obtained. Patients were divided into 4 (O, A, B, and AB groups) according to their blood groups and analyzed for nodules (solitary/ multinodular). Nodules were divided into malignant and benign, according to histopathological diagnosis, and all were analyzed.
Results: There was no difference in analyzing the demographic data according to the blood groups. The rates of the FNAB history were 51 (32.3%), 39 (24.2%), 14 (26.4%), and 13 (32.5%) in the same order of blood groups (p=0.393). In the analysis of the nodule type, multinodular did not differ from solitary nodules among the blood groups [O: 141 (89.2%); A:140(87%), B: 46(86.8%), and AB: 35(87.5%)]. Thyroid function status (euthyroid, hypothyroid, or hyperthyroid) was similar for all the blood groups (p=0.815). The O-group had 1 (0.6%) patient with Bethesda score-6, and the A-group had 2 (1.2%) patients with Bethesda score-6. For Bethesda score-5, per blood group had 2 patients. The histopathological distribution of malign nodules (p=0.782) is as follows: O-groups: 6 (33.3%) (Rh+:27%; Rh-:5,5%), A groups: 7(63,6%) (Rh+:54,5%; Rh-:0,9%), B groups: 2(20%)(Rh+:20%; Rh-:0%) and AB groups: 1(33%) (Rh+:33%) Rh-:0%).
Conclusion: Malign nodule rate was highest in the A-group and lowest in the B groups, although it did not differ in the overall analysis. No relationship was found between the Bethesda categorization of nodules, their sizes, type of nodules, type of thyroid cancer, and ABO blood groups.

Keywords

Thyroid biopsy, Bethesda score, ABO blood group, malign nodule, benign nodule

References

• Zamora EA, Khare S, Cassaro S. Thyroid Nodule. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 5, 2022.
• Ageeli RS, Mossery RA, Othathi RJ, et al. The importance of the thyroid nodule location in determining the risk of malignancy: a retrospective study. Cureus 2022; 14: e29421.
• Abolhasani Foroughi A, Mokhtari M, et al. Concordance between TIRADS and cytology in thyroid nodule. Iran J Otorhinolaryngol 2022; 34: 295-302.
• Yang H, Yan J. A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. Medicine (Baltimore) 2022; 101: e30893.
• Wang J, García-Bailo B, Nielsen DE, El-Sohemy A. ABO genotype, 'blood-type' diet and cardiometabolic risk factors. PLoS One 2014; 9: e84749.
• Liumbruno GM, Franchini M. Hemostasis, cancer, and ABO blood group: the most recent evidence of association. J Thromb Thrombolysis 2014; 38: 160-6.
• Kim DS, Scherer PE. Obesity, diabetes, and increased cancer progression. Diabetes Metab J 2021; 45: 799-812.
• Kremer Hovinga IC, Koopmans M, de Heer E, Bruijn JA, Bajema IM. Change in blood group in systemic lupus erythematosus. Lancet 2007; 369: 186-7.
• Dağdeviren M, Ateş İ, Demir BF, Ergün E, Yıldız C, Altay M. Investigation of blood groups in benign thyroid diseases in Turkey. Endocr J 2019; 66: 1001-9.
• Vierbuchen M, Larena A, Schröder S, et al. Blood group antigen expression in medullary carcinoma of the thyroid. An immunohistochemical study on the occurrence of type 1 chain-derived antigens. Virchows Arch B Cell Pathol Incl Mol Pathol 1992; 62: 79-88.
• Dammann M, Weber F. Personalized medicine: caught between hope, hype and the real world. Clinics (Sao Paulo) 2012; 67: 91-7.
• Tam AA, Özdemir D, Fakı S, Bilginer MC, Ersoy R, Çakır B. ABO blood groups, Rh factor, and thyroid cancer risk: to 'B' or not to 'B'. Endocr Res 2020; 45: 137-46.
• Balázs C. Örökletes és környezeti tényezők szerepe autoimmun pajzsmirigybetegségekben [The role of hereditary and environmental factors in autoimmune thyroid diseases]. Orv Hetil 2012; 153: 1013-22.
• Yu J, Gao F, Klimberg VS, Margenthaler JA. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer. Ann Surg Oncol 2012; 19: 3159-64.
• Stakisaitis D, Juknevičienė M, Ulys A, et al. ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity. Oncol Lett 2018; 16: 1321-31.
• Burgos N, Ospina NS, Sipos JA. The future of thyroid nodule risk stratification. Endocrinol Metab Clin North Am 2022; 51: 305-21.
• Vasan SK, Hwang J, Rostgaard K, et al. ABO blood group and risk of cancer: A register-based cohort study of 1.6 million blood donors. Cancer Epidemiol 2016; 44: 40-3.
• Zivaljevic V, Slijepcevic N, Paunovic I, et al. Risk factors for anaplastic thyroid cancer. Int J Endocrinol 2014; 2014: 815070.
• Sencan M, Celik C, Dogan E, Sevimligul G. Blood group distribution of donors and patients admitted to the Blood and Transfusion Center of Cumhuriyet University Hospital. Cumhuriyet Med J 2015; 37: 23-9.